Treatment of Paget's disease of bone with single dose intravenous pamidronate.
AUTOR(ES)
Watts, R A
RESUMO
OBJECTIVES--To assess the efficacy of a single intravenous infusion of pamidronate in Paget's disease of bone. METHODS--Fourteen patients with active Paget's disease (raised serum alkaline phosphatase, bone pain or neurological involvement) were treated with a single intravenous infusion of 105 mg pamidronate. Patients were assessed for biochemical and clinical improvement for up to two years following treatment. A further infusion was given following symptomatic relapse (pain at a known site of pagetic involvement). RESULTS--Serum alkaline phosphatase fell following treatment, with a nadir 5.9 months after treatment. Bone pain was improved in nine of 12 patients after six months. Retreatment of four patients resulted in a similar response. CONCLUSION--Single dose intravenous pamidronate (105 mg) is a convenient and effective treatment for Paget's disease.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1005123Documentos Relacionados
- Clinical experience with pamidronate in the treatment of Paget's disease of bone.
- Low dose intravenous 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD) for the treatment of Paget's disease of bone.
- Pathophysiology and treatment of Paget's disease of bone
- Paget's Disease of Bone
- Paget's Disease of Bone